Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rizatriptan tablet versus wafer: patient preference.

J U Adelman1, L K Mannix, R L Von Seggern

  • 1Headache Wellness Center, Greensboro, NC 27403, USA.

Headache
|June 10, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study.

Cephalalgia : an international journal of headache·2009
Same author

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine.

Neurology·2008
Same author

Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Neurology·2007
Same author

Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies.

Cephalalgia : an international journal of headache·2007
Same author

Comparative aspects of triptans in treating migraine.

Clinical cornerstone·2003
Same author

Patient satisfaction with rizatriptan versus other triptans: direct head-to-head comparisons.

International journal of clinical practice·2001
Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
Same journal

American Headache Society 68th Annual Scientific Meeting June 4-7, 2026, Orlando, Florida.

Headache·2026
Same journal

In Memoriam-Doctor J. Keith Campbell.

Headache·2026
Same journal

Hypothalamus as a conductor of the migraine prodrome: A narrative review.

Headache·2026
Same journal

New academic year in Headache.

Headache·2026
Same journal

Essential readings in headache medicine: Top 10 educational articles from 2025.

Headache·2026
See all related articles

Patients treated for migraine with rizatriptan showed no group preference between conventional oral tablets and oral disintegrating tablets. Individual patients strongly preferred one migraine medication formulation over the other.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a common neurological disorder.
  • Rizatriptan is an effective medication for acute migraine treatment.
  • Both conventional oral tablets and orally disintegrating tablets are available formulations of rizatriptan.

Purpose of the Study:

  • To determine patient preference between conventional oral rizatriptan tablets and oral disintegrating rizatriptan tablets.
  • To assess if a group preference exists for either rizatriptan formulation in migraine patients.

Main Methods:

  • A 6-month study included adult patients requesting rizatriptan continuation.
  • Patients experienced both conventional and orally disintegrating rizatriptan formulations.
  • Patients were allowed to select their preferred formulation.

Related Experiment Videos

Main Results:

  • 367 patients were included in the study.
  • 188 patients preferred the oral disintegrating tablet.
  • 179 patients preferred the conventional oral tablet.
  • No overall group preference was identified.

Conclusions:

  • Individual patients exhibit strong preferences for specific rizatriptan formulations.
  • No significant group preference was observed between conventional and orally disintegrating rizatriptan tablets for migraine treatment.